Proteomic analysis of JAK2V617F induced changes identifies potential new combinatorial therapeutic approaches.
Williamson, Andrew J K
Blance, Rognvald N
Somervaille, Tim C P
Whetton, Anthony D
AffiliationStem Cell and Leukaemia Proteomics Laboratory, Manchester Academic Health Science Centre, The University of Manchester, Wolfson Molecular Imaging Centre, Withington, Manchester, UK
MetadataShow full item record
AbstractIn excess of 90% of patients with polycythemia vera express a mutated form of JAK2, JAK2V617F. Such aberrant proteins offer great potential for the treatment of these diseases however inhibitors to JAK2 have had limited success in the clinic in terms of curing the disease. To understand the effects of this oncogene in hematopoietic cells with the aim of improving treatment strategies we undertook a systematic evaluation of the effects of JAK2V617F expression using proteomics. The effects of JAK2V617F on over 5000 proteins and 2000 nuclear phosphopeptides sites were relatively quantified using either SILAC or eight channel iTRAQ mass spectrometry. Pathway analysis of the proteins identified as changing indicated disruption to the p53 and MYC signalling pathways. These changes were confirmed using orthogonal approaches. The insight gained from this proteomic analysis led to the formation of hypothesis driven analysis on inhibitor mediated effects on primary cells from patients with a JAK2V617F mutation. Simultaneous inhibition of MYC and up-regulation of p53 led to the preferential extinction of JAK2V617F positive CD34+ cells illustrating a potential therapeutic benefit from combined targeting of p53 and MYC.Leukemia accepted article preview online, 23 May 2017. doi:10.1038/leu.2017.143.
CitationProteomic analysis of JAK2V617F induced changes identifies potential new combinatorial therapeutic approaches. 2017 Leukemia
- Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.
- Authors: Berkofsky-Fessler W, Buzzai M, Kim MK, Fruchtman S, Najfeld V, Min DJ, Costa FF, Bischof JM, Soares MB, McConnell MJ, Zhang W, Levine R, Gilliland DG, Calogero R, Licht JD
- Issue date: 2010 Sep 1
- After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.
- Authors: Grinfeld J, Godfrey AL
- Issue date: 2017 May
- Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
- Authors: Boissinot M, Cleyrat C, Vilaine M, Jacques Y, Corre I, Hermouet S
- Issue date: 2011 Feb 24
- The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera.
- Authors: Falchi M, Varricchio L, Martelli F, Marra M, Picconi O, Tafuri A, Girelli G, Uversky VN, Migliaccio AR
- Issue date: 2017 Jun
- Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.
- Authors: Rubert J, Qian Z, Andraos R, Guthy DA, Radimerski T
- Issue date: 2011 Jan 19